BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


Graham Lewis

Session 1 (Plenary) – Global Biotech Development

Date:27 July (Wednesday)
Time:  09:00 – 10:30 (GMT+8)

Graham Lewis

Vice President, Global Pharma Strategy

An economist by profession, Graham Lewis had, before entering the pharmaceutical industry, widespread experience of international market research, product management and business development at major industrial companies such as Philips and Cadbury Schweppes.

Over the past 30+ years Graham has increasingly focused on strategic issues within the pharmaceutical industry, with particular emphasis on geographical growth opportunities, mergers and acquisitions, portfolio planning, forecasting and optimal launch planning and execution.

He has spoken at conferences in Europe, North America, Latin America and the Far East, including China, and is widely sought after for his strategic insights. 

In May 2002, he was awarded the first Lifetime Achievement Award bestowed by the Pharmaceutical Business Intelligence and Research Group in recognition of his “outstanding lifetime contributions to the Pharmaceutical Industry and Market Research Profession”.

The Strategic Management Review

The Strategic Management Review program provides pharma organizations with an overview of the latest healthcare trends and emerging themes offering a perspective from IQVIA on what the future will look like and how healthcare organizations need to adapt and react.  


IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries. To learn more, visit

Speech title & Synopsis

The‘New Normal’: transforming healthcare and implications for Pharma

In 2023 it is forecasted that COVID-19 will be classified as an endemic infection alongside influenza, thus permitting the emergence of a ‘New Normal’ in healthcare. However, the damage brought to healthcare management, declining economic growth and high inflation are converging and will promote disruptive changes which will have a fundamental impact on the role played by Pharma in meeting healthcare needs. Innovation will be redefined in terms acceptable to Payers, greater rigor will be needed in selecting medicines for commercialization, engagement with customers will become less intimate and more transactional, and in the continuing quest to revitalize pipelines China will begin to play a more fundamental role in discovery and development. 

Success will depend on embracing these changes aiding the recovery of healthcare and its transition to new levels of effective performance, and grasping the rapidly emerging opportunities as digital health transformation moves centre stage